Completed OBSERVATIONAL NCT04932863

BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment (UNICO)

A Prospective Observational Non Interventional Study of Reactogenicity and Safety of the BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

Sponsor: Ente Ospedaliero Ospedali Galliera

Conditions Cancer, Treatment-Related Neoplasms

Interventions BNT162b2 mRNA Covid-19 Vaccine

Updated 7 times since 2021 Last updated: Aug 5, 2025 Started: Mar 15, 2021 Primary completion: Mar 15, 2022 Completion: Mar 15, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04932863, this observational or N/A phase trial focuses on Cancer, Treatment-Related and Neoplasms and remains completed. Sponsored by Ente Ospedaliero Ospedali Galliera, it has been updated 7 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed

Status: Unknown → Completed
Sep 2024 — Sep 2025 [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Feb 2023 — Jul 2023 [monthly]

Recruiting

▶ Show 2 earlier versions

Dec 2021 — Feb 2023 [monthly]

Recruiting
Sep 2021 — Dec 2021 [monthly]

Recruiting

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ente Ospedaliero Ospedali Galliera
Universita degli Studi di Genova

Data source: Ente Ospedaliero Ospedali Galliera

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Genova, Italy